CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

MMJ Recs

NOVEMBER 20, 2023

Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition. These compounds may help reduce symptoms and improve the quality of life for patients. The outcomes of these studies have had a profound impact on patient care.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Veriheal

MARCH 2, 2024

In December of 2023, the country recently made a new move towards reform that could stimulate the cannabidiol (CBD) industry and provide many patients, such as those with epilepsy , with access to potentially life-changing medical treatments. and Europe to treat severe epilepsy, as well as other medical conditions.

Legalization 108

Legalization Epilepsy Clinical Trials THC 108

TheAnswerPage

MARCH 11, 2022

In the clinical trials evaluating a purified CBD product (Epidiolex) in epilepsy patients, side effects including sedation, decreased appetite, diarrhea, sleep disturbance, infections, pneumonia, viral infections and weight loss were reported. ” Kirkland AE, Fadus MC et al. Psych Resear. 308 (2022).

Clinical Trials 52

Clinical Trials Epilepsy Events Sleep 52

MMJ Recs

APRIL 1, 2024

Studies have suggested that CBD may help manage chronic pain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment. Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

SpeedWeed

MARCH 30, 2021

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. However, with the database not yet available to the nation’s private clinics there are concerns over the quality and volume of data it will garner.

Data 52

Data Patients Clinical Trials Business 52

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results. reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

The Cannigma

MAY 9, 2023

However, in 2019, the Jordanian government announced its plans to conduct clinical trials on the use of cannabis for medical purposes. However, the government’s recent announcement of clinical trials on medical cannabis could be a sign of change in the future.

Law 52

Law Clinical Trials Chronic Pain Recreational 52

TheAnswerPage

MAY 25, 2022

The results of recent clinical trials indicate that Cannabidiol (CBD) reduces seizures among patients with refractory epilepsies of various etiologies. Most of these clinical studies report efficacy over short time periods (. The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.

Clinical Trials 52

Clinical Trials Epilepsy Treatment CBD 52

TheAnswerPage

JUNE 29, 2022

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

Cannabis Law Report

JULY 27, 2021

and its Scientific Advisory Board, the Organization Publishes New Real-World Study on Epilepsy and CBD. His first initiative is co-authoring an original study on epilepsy using survey data gathered from RoC’s innovative Observational Research Registry (ORR). Under the Leadership of Nicolas Schlienz, Ph.D., COLORADO SPRINGS, Colo.–(BUSINESS

Data 105

Data Epilepsy Research and Development Clinical Trials 105

TheAnswerPage

JANUARY 9, 2022

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

Canna Care Docs

JUNE 18, 2018

For those who might be exploring the benefits of cannabis or are considering its many therapeutic effects, Cannabidiol, often abbreviated as CBD is especially important for cannabis patients. Cannabinoids are chemicals within cannabis that offer relief to patients, similar to natural compounds in our body called endocannabinoids.

Clinical Trials 75

Clinical Trials CBD Epilepsy Patients 75

TheAnswerPage

JUNE 19, 2021

The results of recent clinical trials indicate that Cannabidiol (CBD) reduces seizures among patients with refractory epilepsies of various etiologies. Most of these clinical studies report efficacy over short time periods (. The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.

Clinical Trials 52

Clinical Trials Epilepsy Treatment CBD 52

MMJ Recs

DECEMBER 17, 2023

Enacted in 2015, the program was designed to provide a narrow avenue for patients suffering from qualifying conditions to access low-THC cannabis under the supervision of qualified healthcare professionals. Physician’s Prescription: Patients must obtain a prescription from a qualified physician registered with the TCUP.

Law 52

Law Clinical Trials Dispensary Programs 52

TheAnswerPage

JULY 13, 2021

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

MMJ Recs

DECEMBER 28, 2023

Medical Marijuana in Cancer Care: Alleviating Pain and Mitigating Chemotherapy Side Effects Cancer patients often endure intense pain and debilitating side effects from chemotherapy. Both THC and CBD play roles in managing these symptoms, with some patients finding relief through the use of specific strains or formulations.

Conditions 98

Conditions Chronic Pain Epilepsy Research and Development 98

Cannabis Law Report

SEPTEMBER 20, 2021

Nanomerics”) to use Nanomeric’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children. VRP324 uses a preassembled device and cartridge to propel the CBD powder formulation into the nose to the brain via the olfactory nerve/bulb.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

Peninsula Alternative Health

MAY 15, 2019

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

MedicalJane

OCTOBER 3, 2019

The United States Department of Defense and GW Pharmaceuticals are collaborating on a new clinical trial at the Montefiore Medical Center in New York. Dr. Eric Hollander, the Director of the Autism and Obsessive Compulsive Spectrum Program and Anxiety and Depression Program at Montefiore Hospital, is leading the clinical trial.

Clinical Trials 74

Clinical Trials Epilepsy Pharmaceutical Treatment 74

Cannabis Law Report

AUGUST 19, 2019

There have been more than 7,500 approvals for medicinal cannabis in Australia since legalisation in 2016 – so why don’t we know if it is helping patients? Access to medicinal cannabis for patients was legalised in Australia in 2016, allowing doctors to request permission to prescribe from the Australian government.

Medicine 45

Medicine Patients Clinical Trials Access 45

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Epidiolex is a CBD-infused oral-based medication designed to help patients as young as two-years-old treat epilepsy disorders.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

United Patients Group

JANUARY 8, 2023

Cannabis has also been used for centuries to treat gastrointestinal disorders, epilepsy, rheumatism and malaria. Many neurological conditions are associated with dysregulation of the ECS (for example: epilepsy, Parkinson’s disease). The post Cannabis and the Immune System appeared first on United Patients Group.

Blood Pressure 122

Blood Pressure Sleep Cannabinoids Clinical Trials 122

The Joint Blog

JANUARY 31, 2021

The study is titled A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extract as complementary therapy: A case report. For the study researchers studied the effects of marijuana extracts in a fifteen-year-old who suffered from autism, anxiety, and controlled epilepsy. ml twice daily.

Epilepsy 62

Epilepsy Extraction Research and Development Clinical Trials 62

MGC Pharma

FEBRUARY 20, 2018

CBD passes Stage 3 clinical trial for the treatment of epilepsy in children A study published last year in The New England Journal of Medicine saw scientists studying the effects of CBD on epileptic seizures in patients with Dravet syndrome, a severe epileptic disorder leading to frequent and uncontrollable seizures in children.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100

Cannabis Law Report

AUGUST 2, 2021

(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. ” About The Study.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

DECEMBER 18, 2019

Notably, the increase comes after the company recently broke into the European pharma-market after getting green-lighted from the Irish Government to sell its phytocannabinoid-derived “CannEpil” product to epilepsy sufferers. Both products are proprietary medicinal drugs developed internally through MGC’s research and development divisions.

Research and Development 59

Research and Development Clinical Trials Seed-To-Sale Pharmaceutical 59

Cannabis Law Report

DECEMBER 23, 2021

However, regulations are constantly shifting beneath the feet of operators and their ability to serve patients depends on their capacity to navigate a changing landscape of governance. Research on the endocannabinoid system is one of the most promising avenues for new therapeutics in medicine at the moment.

Pharmaceutical 96

Pharmaceutical Clinical Trials Research and Development Cannabinoids 96

MMJ Recs

JULY 5, 2024

The use of THC (Tetrahydrocannabinol) has surged dramatically over the years with an increasing interest in the potential health benefits for medical marijuana patients. Neurological Disorders Research suggests THC may benefit neurological conditions such as epilepsy, multiple sclerosis (MS), and Parkinson’s disease.

THC 52

THC Research and Development Chronic Pain Cannabinoids 52

Cannabis Law Report

AUGUST 21, 2019

The watchdog refused to allow its national health service to prescribe medical cannabis for children with severe epilepsy because there is “not enough evidence it works”, a decision which angered campaigners and parents who said their children will suffer as a result. The final guideline is expected to be published in November 2019.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

The Cannigma

MARCH 7, 2022

When CBN was studied without barbiturates (prescription sedative medications typically used for epilepsy), the combination of CBN and THC produced greater sedation together than either cannabinoid alone. What can the current clinical trials tell us?

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Peninsula Alternative Health

MAY 15, 2019

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy.

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Veriheal

MARCH 23, 2023

Aside from Japan legalizing medical marijuana and forging a legal pathway that enables patients to use drugs made from cannabis plants, the amended legal law also seeks to criminalize the use of marijuana. . ‘1948 Law No. Japan’s latest Cannabis Control Law revisions would apply to pharmaceutical-grade medicinal cannabis products.

Legalization 81

Legalization Marijuana Clinical Trials Seed-To-Sale 81

Cannabis Law Report

AUGUST 24, 2021

Thus, there is a great need to develop new and effective therapeutics for treating patients. Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease and decline rather than only addressing the symptoms.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Epilepsy Behav. Available at: www.fda.gov/media/131878/download.

CBD 144

CBD Seed-To-Sale Food Access 144

Medicinal Marijuana Association

AUGUST 27, 2019

Mechoulam’s life path, but also the lives of millions of patients around the world – the ability to isolate the active substance in cannabis formed the foundation for an entire industry basedsolely on a single plant and the variations within its’ strains. The important discoveries made by Prof. Signs of Prof.

Research and Development 66

Research and Development Clinical Trials Patients Epilepsy 66